A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Inclusion Criteria

• •United States of America (USA) specific inclusion criterion:
• •\- Participant must be 12 to \<18 years of age at the time of signing the Informed consent/assent according to local regulation
• •Rest of world (ROW) specific inclusion criterion:
• •\- Participant must be 2 to \<18 years of age at the time of signing the Informed consent/assent according to local regulation
• •Participant has a diagnosis of generalized myasthenia gravis (gMG) confirmed by a prior positive serologic test result to acetylcholine receptor (AChR) prior to Screening
• •Participant meets the criteria as defined by the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification II to IV at Screening
• •Participants with gMG, including:
• •An MG-activities of daily living (MG-ADL) total score of 6 or more in adolescents from 12 years to \<18 years of age at Screening
• •Documented weakness in at least 1 limb, neck, or bulbar muscle in children from 2 years to \<12 years of age at Screening (does not apply to US)
• •Documented vaccination against meningococcal infections within 3 years prior to study start. If not fully vaccinated, participants must receive appropriate prophylactic antibiotic treatment until at least 2 weeks after the initial dose of vaccine(s)